Risk factors for tonsillar hypertrophy and post-transplant lymphoproliferative disorder

Area of Science:

• Immunology
• Transplant Medicine
• Pediatric Oncology

Background:

• Post-transplant lymphoproliferative disorder (PTLD) is a rare but serious complication following solid organ transplantation, often linked to immunosuppression.
• Tonsillar hypertrophy is a common manifestation of PTLD, frequently leading to tonsillectomy in affected children.
• Identifying risk factors for PTLD-mediated tonsillar hypertrophy is crucial for preemptive management and improved patient outcomes.

Purpose of the Study:

• To identify clinical and therapeutic factors associated with the development of tonsillar hypertrophy in pediatric patients diagnosed with PTLD.
• To investigate the relationship between specific immunosuppressive agents and the incidence of tonsil disease in pediatric transplant recipients.
• To provide data that can guide clinical decision-making and potentially mitigate PTLD-related complications.

Main Methods:

• A retrospective cohort study was conducted utilizing the TriNetX Database.
• The study population comprised pediatric solid organ transplant recipients.
• Data on tonsil disease, tonsillectomy, PTLD diagnosis, transplant history, and immunosuppressant medications were extracted using relevant medical codes.

Main Results:

• Out of 21,582 pediatric transplant patients, 8.49% had tonsil disease, with 10.53% of those diagnosed with PTLD within six months.
• Tacrolimus (OR 2.74), mycophenolate mofetil (OR 2.72), and cyclosporine (OR 1.50) were associated with increased rates of tonsil disease.
• Sirolimus showed a protective association (OR 0.66), while Epstein-Barr virus (EBV) diagnosis correlated with higher rates of both tonsil disease (OR 1.45) and PTLD (OR 3.52).

Conclusions:

• This study represents the largest investigation into tonsillar hypertrophy in PTLD and the first to link tacrolimus, mycophenolate mofetil, and cyclosporine to increased tonsil disease risk in pediatric transplant patients.
• The findings highlight specific immunosuppressants as significant risk factors for PTLD-mediated tonsil disease.
• Understanding these risk factors is vital for developing strategies to prevent or manage this complication in immunosuppressed pediatric populations.